Form RW - Registration Withdrawal Request
02 Août 2023 - 9:11PM
Edgar (US Regulatory)
EOM
PHARMACEUTICAL HOLDINGS, INC.
136
Summit Avenue
Montvale,
NJ 07645
August
2, 2023
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
|
Re: |
EOM
Pharmaceutical Holdings, Inc.
|
|
|
(formerly known
as Immunocellular Therapeutics, Ltd.) |
|
|
Request
for Withdrawal of Registration Statement on Form S-1 |
|
|
Filed
on June 24, 2022 |
|
|
File
No. 333-265817 |
Ladies
and Gentlemen:
Pursuant
to Rule 477 of the Securities Act of 1933, as amended (“Securities Act”), EOM Pharmaceutical Holdings, Inc.,
a Delaware corporation (formerly known as Immunocellular Therapeutics, Ltd., the “Company”), hereby
respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal
of the Registration Statement on Form S-1 (File No. 333-265817), together with all exhibits and amendments thereto, as initially filed
with the Commission on June 24, 2022 (collectively, “Registration Statement”), effective immediately or at
the earliest practicable date hereafter.
The
Company is seeking withdrawal of the Registration Statement because it opted not to pursue the offering contemplated thereby. The Company
confirms that the Registration Statement has not been declared effective and that no securities have been sold pursuant to the Registration
Statement.
Accordingly,
the Company requests that the Commission issue an order granting the withdrawal of the Registration Statement (the “Order”)
effective as of the date hereof or at the earliest practicable date hereafter. Please provide a copy of the Order to the undersigned
at the above address, with a copy to Louis A. Brilleman, counsel for the Company, via email at lbrilleman@lbcounsel.com.
Additionally,
in accordance with Rule 457(p) of the Securities Act, the Company requests that all fees paid to the Commission in connection with the
initial filing of the Registration Statement be credited for future use by the Company.
Should
you have any questions regarding this request for withdrawal, or if you require any additional information, please contact Louis A. Brilleman
by telephone at (212) 537-5852.
|
Very truly yours, |
|
|
|
|
|
/s/
Eli Goldberger |
|
Name: |
Eli Goldberger |
|
Title: |
Chairman |
EOM Pharmaceutical (PK) (USOTC:IMUC)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
EOM Pharmaceutical (PK) (USOTC:IMUC)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about EOM Pharmaceutical Holdings Inc (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur EOM Pharmaceutical Holdings Inc (PK)